TMEM160

Across TCGA pan-cancer cohorts, TMEM160 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TMEM160 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMEM160 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM160 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where TMEM160 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.227	0.932	.002	17	view →
PDAC	DFS	Quartile	All	0.230	0.628	.010	12	view →
HNSC	DFS	Quartile	All	0.771	0.505	.011	9	view →
LSCC	DFS	Tertile	All	1.000	0.937	.029	7	view →
UCEC	DFS	Tertile	All	0.846	0.971	.027	6	view →
GBM	DFS	Median	All	0.225	0.481	.009	5	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TMEM160–CCRCC (DFS)

Open the CCRCC breakdown →